WHITE PAPER
IQVIA Pharma Deals: Half-year review of 2022
IQVIA Pharma Deals
Sep 27, 2022

Deal activity in the life sciences sector in H1 2022 was unable to match the pandemic-boosted level seen in H1 2021 as challenging market and economic conditions deterred companies from pursuing certain types of transactions. After rebounding in H1 2021 following the hiatus brought about by the emergence of COVID-19, M&A activity dropped off significantly in H1 2022 both in terms of deal volume and value as the life sciences sector declined in value and caution prevailed among potential purchasers amid much economic and geopolitical uncertainty.

Related solutions

Contact Us